About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park Comprehensive Cancer Center has been working to understand the …
RNA sequencing reveals how venetoclax enhances CAR T cell function in treatment-resistant lymphoma
Share.
